<DOC>
	<DOCNO>NCT01950182</DOCNO>
	<brief_summary>The primary objective study compare progression-free survival ( PFS ) patient metastatic Luminal B2 breast cancer subtype randomise treatment Trastuzumab Combined With Chemotherapy Endocrine Therapy .</brief_summary>
	<brief_title>Trastuzumab Combined With Chemotherapy Endocrine Therapy Treat Metastatic Luminal B2 Breast Cancer</brief_title>
	<detailed_description>This non-inferiority study examine Trastuzumab combine chemotherapy endocrine therapy patient metastatic Luminal B2 breast cancer subtype . The main purpose study test safety clinical benefit Trastuzumab combine chemotherapy endocrine therapy treat Luminal B2 breast cancer ( hormone receptor positive human epidermal growth factor receptor ( HER2 ) positive amplification ) . This multicentre , randomize study design recruit 392 subject identify 196 research subject study treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>1 . Age 18 year old . 2 . Patients Eastern Cooperative Oncology Group ( ECOG ) score 0 1 . 3 . Histologically confirm metastatic local recurrence breast cancer . 4 . ER positive and/or progesterone receptor ( PR ) positive , HER2+ define immunohistochemistry3+ stain FISH+ . 5 . Prior adjuvant Trastuzumab therapy permit , diseasefree interval ( DFI ) must 12 month . 6 . Patients must measurable evaluable disease . 7 . Adequate bone marrow reserve neutrophil &gt; 1000 platelet &gt; 100,000 . 8 . Adequate renal function serum creatinine &lt; 2.0 . 9 . Adequate hepatic reserve serum bilirubin &lt; 2.0 , alanine transaminase ( ALT ) &lt; 3 time upper limit normal , alkaline phosphatase &lt; 5 time upper limit normal . 10 . Adequate cardiac reserve least 45 % Left ventricular ejection fraction ( LVEF ) echocardiogram . 11 . Able give inform consent . 12 . Life expectancy least 12 week . 1 . Pregnant breast feeding . 2 . ECOG score â‰§2 3 . DFI &lt; 12 month . 4 . LVEF &lt; 45 % echocardiogram . 5 . Uncontrolled medical problem . 6 . Evidence active acute chronic infection . 7 . Hepatic , renal , bone marrow dysfunction detail . 8 . Concurrent malignancy history malignancy within last five year except note . 9 . Known severe hypersensitivity Trastuzumab . 10 . Patients unable unwilling comply program requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Luminal B2 subtype</keyword>
	<keyword>First line treatment</keyword>
</DOC>